Hemispherx Biopharma Introduces a Voluntary Stock Purchase Plan to Create Shareholder Value
February 03, 2016 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Feb. 03, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) announced today, February 3, 2016, a Voluntary Pay for Stock Plan (the “Plan”). Hemispherx Biopharma...
Hemispherx Biopharma Europe N.V./S.A. : Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Alferon N Injection® as a Treatment of Middle East Respiratory Syndrome (MERS)
January 20, 2016 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 20, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the “Company” or “Hemispherx”) announces that the European Medicines Agency (EMA) on January 6, 2016 has...
Hemispherx Biopharma Announces Financial Results for the Nine Months Ended September 30, 2015
November 17, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Nov. 17, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced its financial results for the nine months ended September 30, 2015. The net loss (including non-cash...
New Arrowhead Analyst Issues Updated Diligence and Valuation Report on Hemispherx Biopharma
September 30, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 30, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announces that Arrowhead BID issued an analyst report on September 29, 2015,...
Hemispherx Biopharma Receives the European Patent Office Grant of New Composition of Matter Patent Covering Ampligen(R) Formulations
September 28, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 28, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that it received formal notice on September 21, 2015, that the...
Hemispherx Biopharma Reports Article by Senior Authors From Italian Ministry of Health and Related Agencies Suggesting Broad Applicability of Ampligen(R) to Multiple Sclerosis
September 23, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 23, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today a new peer reviewed article, with senior authors from the Italian Ministry of Health and other...
Hemispherx Biopharma Announces Patient Assistance Program for Chronic Fatigue Syndrome Open Label Study
September 17, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 17, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today the approval by the Board of Directors for a Patient...
Hemispherx Biopharma Reports Low NK Cell Activity in Chronic Fatigue Syndrome (CFS) and Relationship to Disease Symptoms
September 15, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 15, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today the publication in the current issue of the peer reviewed Journal of Clinical and Cellular...
Hemispherx Biopharma to Present at the 17th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10, 2015
September 02, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 2, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) today announced it will be featured as a presenting company at the 17th Annual Rodman & Renshaw Global...
Photo Release -- Hemispherx Biopharma Fully Aligns Executive Bonus Programs to Accelerate Product Revenue Opportunities and Market Entry
August 31, 2015 08:30 ET
|
AIM ImmunoTech Inc.
NEW BRUNSWICK, N.J., Aug. 31, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) recently hosted a Stockholder Open House in their manufacturing and Research and Development (R&D)...